Tirzepatide vs Semaglutide Brands: Which GLP-1 Is Right for You?

Filipino patients walking into a Metro Manila weight-management clinic in 2026 have three branded GLP-1 options to choose between, plus a growing grey market for compounded variants and the next-generation triple-agonist retatrutide. The choice between them is not as obvious as the marketing suggests. They have different mechanisms, different weight-loss outcomes, different side-effect profiles, and very different price tags at major Philippine retail pharmacy chains.

This guide compares tirzepatide (branded tirzepatide products), semaglutide at diabetes dosing (branded semaglutide), and semaglutide at weight-loss dosing (high-dose branded semaglutide) across the dimensions that actually matter for a Filipino buyer: published trial outcomes, dosing schedules, side-effect frequency, local availability, and 2026 Philippine pricing.

For the broader pillar context on tirzepatide as a molecule, see our Tirzepatide Philippines complete guide. For the head-to-head branded tirzepatide versus branded semaglutide question specifically, see branded tirzepatide vs branded semaglutide for weight loss. For verifying any of these molecules before injection, see how to spot fake tirzepatide and branded semaglutide.

The three molecules at a glance

The headline takeaway: tirzepatide produces the largest weight-loss effect in published trials. high-dose branded semaglutide is the regulatory-approved semaglutide product for chronic weight management. branded semaglutide is the diabetes label that most Filipino off-label weight-loss prescriptions still run through, since high-dose branded semaglutide distribution remains thin locally.

Weight loss: what the trials actually show

Tirzepatide (SURMOUNT-1): 2,539 adults with obesity, no diabetes, randomised to placebo or tirzepatide at 5, 10, or 15 mg weekly. Mean body weight reduction at 72 weeks: 16.0%, 21.4%, and 22.5% respectively. Placebo: 3.1%. Published in New England Journal of Medicine, June 2022.

Semaglutide 2.4 mg / high-dose branded semaglutide (STEP-1): 1,961 adults with overweight or obesity, no diabetes, randomised to placebo or semaglutide 2.4 mg weekly. Mean body weight reduction at 68 weeks: 14.9% on drug versus 2.4% on placebo. Published in New England Journal of Medicine, March 2021.

Semaglutide 1 mg / branded semaglutide (SUSTAIN trials): weight loss of 4 to 6% on average in type 2 diabetes patients. Off-label use at 2 mg pushes the effect closer to 8 to 10%, but data is observational and not as clean as STEP-1.

Direct head-to-head: SURPASS-2 compared tirzepatide and semaglutide 1 mg in type 2 diabetes patients (HbA1c primary endpoint, weight loss secondary). Tirzepatide produced significantly greater weight reduction at all doses than semaglutide 1 mg.

The expected weight-loss order from largest to smallest, at maximum tolerated dose: tirzepatide > semaglutide 2.4 mg (high-dose branded semaglutide) > semaglutide 1 to 2 mg (branded semaglutide). Individual response varies; some patients respond better to one molecule than another for reasons not fully understood.

Side effects: similar profile, different intensity

All three molecules share the same broad side-effect profile because the mechanisms overlap. The most common, in approximate order of frequency:

• Nausea (25 to 45% of patients, dose-dependent).
• Diarrhoea or constipation (15 to 25%).
• Vomiting (5 to 15%).
• Fatigue (5 to 15%).
• Injection-site reactions (rare, less than 5%).

Tirzepatide produces somewhat more frequent gastrointestinal side effects at higher doses than semaglutide, in part because the dual-receptor activity is more potent overall. Most Filipino patients tolerate the titration schedule when stepped up slowly and given anti-emetic support if needed.

Less common but more serious adverse events across all three:

• Acute pancreatitis (rare).
• Gallbladder disease, particularly with rapid weight loss.
• Black-box warning for thyroid C-cell tumours from rodent studies (contraindicated in personal or family history of medullary thyroid carcinoma or MEN2 syndrome).

For a deeper analysis of side effects specifically with tirzepatide, see tirzepatide side effects.

Dosing: schedule, escalation, pen mechanics

Tirzepatide (the branded tirzepatide pen):

• Start at 2.5 mg weekly for 4 weeks.
• Step up to 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg in 4-week increments based on tolerance.
• Each branded pen contains four weekly doses at one fixed strength. Dose escalation requires switching to a new pen strength.

Semaglutide / branded semaglutide (branded multi-dose pen):

• Start at 0.25 mg weekly for 4 weeks.
• Step up to 0.5 mg, 1 mg, then optionally 2 mg.
• The 0.25/0.5 mg pen and the 1 mg pen and the 2 mg pen are different products. Each branded multi-dose pen contains four weekly doses across the dial range it supports.

Semaglutide / high-dose branded semaglutide:

• Start at 0.25 mg weekly for 4 weeks.
• Step up to 0.5 mg, 1 mg, 1.7 mg, 2.4 mg in 4-week increments.
• Pre-filled single-use pens, one per dose strength.

Practical Filipino consideration: the branded tirzepatide pen requires more pen-switching during titration than branded semaglutide. Patients on a 4-week titration cycle may go through five different branded pen before reaching the 15 mg target dose. high-dose branded semaglutide in markets with full distribution is similar.

Pricing in the Philippines (2026)

The straight cost ratio: branded tirzepatide is roughly 60 to 80% more expensive per month than branded semaglutide for the larger weight-loss outcome. high-dose branded semaglutide in the Philippines is currently priced as a specialty import and is not consistently stocked at registered Philippine pharmacy chains.

For the detailed price breakdown across all channels, see tirzepatide price Philippines.

The grey-market complication: retatrutide and compounded variants

In 2025 and into 2026, the Filipino grey market has begun to surface compounded tirzepatide vials, compounded semaglutide vials, and a small but growing supply of retatrutide, the next-generation triple agonist (GLP-1 + GIP + glucagon) currently in late-stage clinical trials.

The phase 2 retatrutide trial (Jastreboff et al., NEJM 2023) showed up to 24.2% weight reduction at 48 weeks, larger than tirzepatide. The molecule is not approved by FDA Philippines, FDA US, or EMA as of early 2026. Any retatrutide on the Philippine grey market is research-grade compound or counterfeit; both carry analytical risk.

Compounded tirzepatide and compounded semaglutide are produced by compounding pharmacies (mostly US-based, some Asian) selling vials that are not branded the manufacturer or the manufacturer product. The molecule may be authentic, underdosed, or substituted. Visual inspection cannot distinguish them.

For the full counterfeit pattern analysis, see how to spot fake tirzepatide and branded semaglutide.

Decision framework for Filipino patients

The choice between the three molecules in 2026:

Choose tirzepatide (branded tirzepatide) if:

• Your weight-loss target is more than 15% body weight.
• You can absorb the higher monthly cost.
• You have access to consistent branded pen supply at registered Philippine pharmacy chains.
• You tolerate or can manage stronger gastrointestinal side effects.

Choose semaglutide (branded semaglutide) if:

• Your weight-loss target is 5 to 12% body weight.
• You want the more established cardiovascular outcome data.
• Your budget caps at PHP 14,000 to 18,000 per month.
• You have type 2 diabetes (the on-label indication, which simplifies prescription).

Choose semaglutide (high-dose branded semaglutide) if:

• You can source it through specialty import channels.
• You specifically want the on-label weight-management product.
• Cost is not the primary constraint.

Avoid the grey market and retatrutide unless:

• You understand the analytical risk.
• You are prepared to verify any vial through independent third-party laboratory analysis before use.
• You are working with a clinician who is comfortable with research-grade compounds.

Verification across all three molecules

Regardless of which compound you choose, the authentication question is the same. Authentic the manufacturer branded pen, the manufacturer branded multi-dose pen, and the branded semaglutide weight-management pen have specific visual and engineering signatures. Counterfeit versions of all three exist in Southeast Asia.

Lumen Labs runs the same analytical pathway on each:

• HPLC purity at the relevant absorbance wavelength.
• LC-MS identity against the published mass (tirzepatide 4813.5 Da, semaglutide 4113.6 Da, retatrutide 4731.3 Da).
• Quantitation in milligrams per millilitre against the labelled dose.
• Optional endotoxin (LAL) and microbial limits (USP 61).

The output is a certificate of analysis showing whether the submitted sample matches the label. Five outcomes: pass, underdosed, wrong API, no API, contaminated.

Compounded tirzepatide is a particularly important verification target because the compounding pharmacy supply chain is less regulated than the manufacturer or the manufacturer. The molecule may be present, but at a different concentration than the label claims. For oral collagen and other supplements, verification follows similar logic; see collagen peptides Philippines for the supplement-category equivalent of this analysis.

Bottom line

Tirzepatide produces the largest weight-loss effect in published trials and is the most expensive of the three. Semaglutide at high-dose branded semaglutide doses (2.4 mg) is the FDA-approved weight-management label and produces approximately two-thirds of the tirzepatide effect. Semaglutide at branded semaglutide doses (1 to 2 mg) is the diabetes label most commonly used off-label for weight loss in the Philippines, with smaller weight-loss outcomes than high-dose branded semaglutide.

For a Filipino patient choosing between the three in 2026, the decision is mostly a function of weight-loss goal magnitude, monthly budget, and tolerance for the pen-switching schedule. The grey market is cheaper but introduces authentication risk that can only be resolved through independent third-party laboratory analysis.

Whichever molecule you choose, verify it before you inject it. The cost of one Lumen Labs test is small compared with the cost of injecting a counterfeit or underdosed product for months.

Disclaimer: Lumen Labs provides chemical analysis of submitted samples for harm-reduction and quality-verification purposes. We are not a substitute for medical care. Tirzepatide, semaglutide, and retatrutide are prescription or research compounds depending on jurisdiction; consult a qualified Philippine licensed physician before starting, adjusting, or stopping any therapy.